UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
(Address of principal executive offices, including Zip Code)
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol |
Name of each exchange on which registered | ||
(Nasdaq Global Select Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 | Other Events. |
On July 31, 2023, Aligos Therapeutics, Inc. (the “Company”) and Janssen Biopharma, LLC (“Janssen”) filed a stipulation staying the case in their ongoing legal proceedings. The Company and Janssen have reached an agreement in principle to resolve their disputes and expect to finalize a settlement agreement promptly.
Forward-Looking Statements
This report contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this report that are not historical facts may be considered “forward-looking statements,” including, but not limited to the Company’s expectation that a settlement will be reached promptly. Forward-looking statements are typically, but not always, identified by the use of words such as “may,” “will,” “would,” “believe,” “intend,” “plan,” “anticipate,” “estimate,” “expect,” and other similar terminology indicating future results. Such forward-looking statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of the Company in general, see the Company’s Annual Report on Form 10-Q filed with the Securities and Exchange Commission on May 4, 2023, as well as other documents the Company files from time to time with the Securities and Exchange Commission. Except as required by law, the Company undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ALIGOS THERAPEUTICS, INC. | ||||||
Date: August 1, 2023 | By: | /s/ Lesley Ann Calhoun | ||||
Lesley Ann Calhoun | ||||||
Executive Vice President, Chief Financial Officer |
Document and Entity Information |
Jul. 31, 2023 |
---|---|
Cover [Abstract] | |
Amendment Flag | false |
Entity Central Index Key | 0001799448 |
Document Type | 8-K |
Document Period End Date | Jul. 31, 2023 |
Entity Registrant Name | Aligos Therapeutics, Inc. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-39617 |
Entity Tax Identification Number | 82-4724808 |
Entity Address, Address Line One | One Corporate Dr. |
Entity Address, Address Line Two | 2nd Floor |
Entity Address, City or Town | South San Francisco |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94080 |
City Area Code | (800) |
Local Phone Number | 466-6059 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, $0.0001 par value per share |
Trading Symbol | ALGS |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
-8?20$3;8T.P6BP^0"X99K>]
M9!:G
01'..ZXMA3=V9 '"1^\7B\3O,^'L]!(J,:S"EHJ(1
M!FST*QOG,BBMZ+ E:B60G>/3TTKE9!&_XAQE%.LR!6J+:;A'&:YJ*W$P%['B
M7T75<9'3?! )9!S[K*\0%13Q?"K/A9$.TF:J?"5QBS;6%B^@AR[/B[/K258_
MLV)[KV6LW*T5H&I";KM[&Y ['<;LYDUN>8 /NIPI8E%@2\6[UOAU=L/F!R/6
M2^%'L*,RF-R"9"OSD1IV.<4M'3EMF^(:K.B;MDRFG "#V^/I>P2TV>(8*RXX3"^/O+[-.PQ \/7.VGG+V6FCE2JG@('[(>'SO0K!+(;A7#/4V5I_:JB&TO.JNV]W>
M6_\#"<-:S@2JY?T,V5*.7Z?Q-Q"@(%_>ZWS8K0@YF.]"]$I"U- Z9NI=E-Y8
ME Y8OK+G[U:4$I@;B]*NHZ^,D^C"'*8@4(I6EMRAW*>Q#ZQV=:CS7HKQARW%
M>,[A[ 99BQ6K72(Y;WH>U,8WOES%I-\GOJ!:O]9)W7.)^,;G>6U%47C?_"2O
M-1Y T_MF/9W&34H4+7>SQ+"]^=;)D( B (RF1FK65'ZSU68KDP7.\(Z](Z;U]774;[7BTG=S9<_D1_&8B.3-.YV"QS]+&P#HBK2^R
M88O-G6V4@>0L9AD3DWO\,5;,6#N.69FRNL#*W%I:[FRF/"DP0P[P:BF_#V+N
M0*O'\?CX:?&E"-6E]Y+K#<4/[NRA[&33U7H.ZOM9EL1QAFB)=\O5G8V5 <1S
M8S&,1D.6\:,O)?=UU>6V[]5R